This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lavigueur, A
Right arrow Articles by Bernstein, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lavigueur, A
Right arrow Articles by Bernstein, A

 Previous Article  |  Next Article 

Mol Cell Biol. 1989 September; 9(9): 3982-3991

High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.

A Lavigueur, V Maltby, D Mock, J Rossant, T Pawson and A Bernstein

Division of Molecular and Developmental Biology, Mount Sinai Hospital Research Institute, Toronto, Ontario, Canada.

ABSTRACT

We have investigated the role of the p53 gene in oncogenesis in vivo by generating transgenic mice carrying murine p53 genomic fragments isolated from a mouse Friend erythroleukemia cell line or BALB/c mouse liver DNA. Elevated levels of p53 mRNA were detected in several tissues of two transgenic lines tested. Increased levels of p53 protein were also detected in most of the tissues analyzed by Western blotting (immunoblotting). Because both transgenes encoded p53 proteins that were antigenically distinct from wild-type p53, it was possible to demonstrate that overexpression of the p53 protein was mostly, if not entirely, due to the expression of the transgenes. Neoplasms developed in 20% of the transgenic mice, with a high incidence of lung adenocarcinomas, osteosarcomas, and lymphomas. Tissues such as ovaries that expressed the transgene at high levels were not at higher risk of malignant transformation than tissues expressing p53 protein at much lower levels. The long latent period and low penetrance suggest that overexpression of p53 alone is not sufficient to induce malignancies and that additional events are required. These observations provide direct evidence that mutant alleles of the p53 oncogene have oncogenic potential in vivo and that different cell types show intrinsic differences in susceptibility to malignant transformation by p53. Since recent data suggest that p53 may be a recessive oncogene, it is possible that the elevated tumor incidence results from functional inactivation of endogenous p53 by overexpression of the mutant transgene. The high incidence of lung and bone tumors suggests that p53 transgenic mice may provide a useful model to investigate the molecular events that underlie these malignancies in humans.

Mol Cell Biol. 1989 September; 9(9): 3982-3991




This article has been cited by other articles:

  • Simmons, S. O., Fan, C.-Y., Ramabhadran, R. (2009). Cellular Stress Response Pathway System as a Sentinel Ensemble in Toxicological Screening. Toxicol Sci 111: 202-225 [Abstract] [Full Text]  
  • Wijnhoven, S. W.P., Speksnijder, E. N., Liu, X., Zwart, E., vanOostrom, C. Th. M., Beems, R. B., Hoogervorst, E. M., Schaap, M. M., Attardi, L. D., Jacks, T., van Steeg, H., Jonkers, J., de Vries, A. (2007). Dominant-Negative but not Gain-of-Function Effects of a p53.R270H Mutation in Mouse Epithelium Tissue after DNA Damage. Cancer Res. 67: 4648-4656 [Abstract] [Full Text]  
  • Wunder, J. S., Gokgoz, N., Parkes, R., Bull, S. B., Eskandarian, S., Davis, A. M., Beauchamp, C. P., Conrad, E. U., Grimer, R. J., Healey, J. H., Malkin, D., Mangham, D.C., Rock, M. J., Bell, R. S., Andrulis, I. L. (2005). TP53 Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study. JCO 23: 1483-1490 [Abstract] [Full Text]  
  • Suggitt, M., Bibby, M. C. (2005). 50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches. Clin. Cancer Res. 11: 971-981 [Abstract] [Full Text]  
  • Chan, J. K., Loizzi, V., Magistris, A., Lin, F., Rutgers, J., Osann, K., DiSaia, P. J., Berman, M. L. (2004). Differences in Prognostic Molecular Markers between Women Over and Under 45 Years of Age with Advanced Ovarian Cancer. Clin. Cancer Res. 10: 8538-8543 [Abstract] [Full Text]  
  • Lubet, R. A., Zhang, Z., Wang, Y., You, M. (2004). Chemoprevention of Lung Cancer in Transgenic Mice. Chest 125: 144S-147S [Full Text]  
  • Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., Scrable, H. (2004). Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18: 306-319 [Abstract] [Full Text]  
  • Wang, Y., Zhang, Z., Kastens, E., Lubet, R. A., You, M. (2003). Mice with Alterations in Both p53 and Ink4a/Arf Display a Striking Increase in Lung Tumor Multiplicity and Progression: Differential Chemopreventive Effect of Budesonide in Wild-type and Mutant A/J Mice. Cancer Res. 63: 4389-4395 [Abstract] [Full Text]  
  • Das, S., El-Deiry, W. S., Somasundaram, K. (2003). Regulation of the p53 Homolog p73 by Adenoviral Oncogene E1A. J. Biol. Chem. 278: 18313-18320 [Abstract] [Full Text]  
  • Chen, Y.-Q., Zhou, Y.-Q., Fu, L.-H., Wang, D., Wang, M.-H. (2002). Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Carcinogenesis 23: 1811-1819 [Abstract] [Full Text]  
  • Tchou-Wong, K.-M., Jiang, Y., Yee, H., LaRosa, J., Lee, T. C., Pellicer, A., Jagirdar, J., Gordon, T., Goldberg, J. D., Rom, W. N. (2002). Lung-Specific Expression of Dominant-Negative Mutant p53 in Transgenic Mice Increases Spontaneous and Benzo(a)pyrene-Induced Lung Cancer. Am. J. Respir. Cell Mol. Bio. 27: 186-193 [Abstract] [Full Text]  
  • Hursting, S. D., Perkins, S. N., Donehower, L. A., Davis, B. J. (2001). Cancer Prevention Studies in p53-Deficient Mice. Toxicol Pathol 29: 137-141 [Abstract]  
  • Liu, G., McDonnell, T. J., Montes de Oca Luna, R., Kapoor, M., Mims, B., El-Naggar, A. K., Lozano, G. (2000). High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc. Natl. Acad. Sci. USA 97: 4174-4179 [Abstract] [Full Text]  
  • Laverdiere, M., Beaudoin, J., Lavigueur, A. (2000). Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene. Nucleic Acids Res 28: 1489-1497 [Abstract] [Full Text]  
  • Clarke, A. R. (2000). Manipulating the germline: its impact on the study of carcinogenesis. Carcinogenesis 21: 435-441 [Abstract] [Full Text]  
  • Zhang, Z., Liu, Q., Lantry, L. E., Wang, Y., Kelloff, G. J., Anderson, M. W., Wiseman, R. W., Lubet, R. A., You, M. (2000). A Germ-Line p53 Mutation Accelerates Pulmonary Tumorigenesis: p53-independent Efficacy of Chemopreventive Agents Green Tea or Dexamethasone/myo-Inositol and Chemotherapeutic Agents Taxol or Adriamycin. Cancer Res. 60: 901-907 [Abstract] [Full Text]  
  • Loging, W. T., Reisman, D. (1999). Elevated Expression of Ribosomal Protein Genes L37, RPP-1, and S2 in the Presence of Mutant p53. Cancer Epidemiol. Biomarkers Prev. 8: 1011-1016 [Abstract] [Full Text]  
  • Huang, C., Ma, W.-y., Li, J., Dong, Z. (1999). Arsenic Induces Apoptosis through a c-Jun NH2-Terminal Kinase-dependent, p53-independent Pathway. Cancer Res. 59: 3053-3058 [Abstract] [Full Text]  
  • Clewell, H. J., Gentry, P. R., Barton, H. A., Shipp, A. M., Yager, J. W., Andersen, M. E. (1999). Requirements for a Biologically Realistic Cancer Risk Assessment for Inorganic Arsenic. International Journal of Toxicology 18: 131-147 [Abstract]  
  • Bedell, M A, Largaespada, D A, Jenkins, N A, Copeland, N G (1997). Mouse models of human disease. Part II: recent progress and future directions.. Genes Dev. 11: 11-43  
  • Guidos, C J, Williams, C J, Grandal, I, Knowles, G, Huang, M T, Danska, J S (1996). V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors.. Genes Dev. 10: 2038-2054 [Abstract]  
  • Donehower, L A, Godley, L A, Aldaz, C M, Pyle, R, Shi, Y P, Pinkel, D, Gray, J, Bradley, A, Medina, D, Varmus, H E (1995). Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability.. Genes Dev. 9: 882-895 [Abstract]  
  • Harris, C. (1993). p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262: 1980-1981  
  • Pories, S. E., Ramchurren, N., Summerhayes, I., Steele, G. (1993). Animal Models for Colon Carcinogenesis. Arch Surg 128: 647-653 [Abstract]  
  • Adams, J., Cory, S (1991). Transgenic models of tumor development. Science 254: 1161-1167 [Abstract]  
  • Malkin, D, Li, F., Strong, L., Fraumeni, J. Jr, Nelson, C., Kim, D., Kassel, J, Gryka, M., Bischoff, F., Tainsky, M., et, al. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238 [Abstract]  
  • Sager, R (1989). Tumor suppressor genes: the puzzle and the promise. Science 246: 1406-1412 [Abstract]  
  • Takahashi, T, Nau, M., Chiba, I, Birrer, M., Rosenberg, R., Vinocour, M, Levitt, M, Pass, H, Gazdar, A., Minna, J. (1989). p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494 [Abstract]  
  • Pasumarthi, K. B. S., Tsai, S.-C., Field, L. J. (2001). Coexpression of Mutant p53 and p193 Renders Embryonic Stem Cell-Derived Cardiomyocytes Responsive to the Growth-Promoting Activities of Adenoviral E1A. Circ. Res. 88: 1004-1011 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»